Second-Line Therapy for Type 2 #Diabetes Management: The Treatment/Benefit Paradox of #Cardiovascular and #Kidney Comorbidities

To examine whether glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) are preferentially initiated among patients with cardiovascular disease, heart failure (HF), or nephropathy, where these drug classes have established benefit, compared with dipeptidyl peptidase 4 inhibitors (DPP-4i), for which corresponding benefits have not been demonstrated. RESEARCH DESIGN AND METHODS We …

Continue reading Second-Line Therapy for Type 2 #Diabetes Management: The Treatment/Benefit Paradox of #Cardiovascular and #Kidney Comorbidities